Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Recruiting · Phase 3 · NCT05950945
Conditions: Breast Cancer
At a glance
- Research payments reported, 2025
- $408,941
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 250
About the trial
- Sponsor
- Daiichi Sankyo (with AstraZeneca)
- Tested
- Trastuzumab Deruxtecan (drug)
- Dates
- Started 2023-12-30; completion 2027-10-01
- Results posted
- Not yet
This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor \[HR\]-negative and HR-positive) unresectable and/or metastatic breast cancer.
From ClinicalTrials.gov, last updated 2026-06-12. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $408,941 in research payments for this study in 2025 (132 payments).
Products named: Enhertu
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Oleg Gligich, M.D Hematology & Oncology · Miami Beach, FL
- Jamie E. Mckenzie, MD Hematology & Oncology · Tampa, FL
- Amelia B. Zelnak, MD Hematology & Oncology · Cumming, GA
- Maria Galkin, MD Hematology & Oncology · Burlington, MA
- Sara M. Tolaney, MD Hematology & Oncology · Boston, MA
- Bonni L. Guerin, MD Hematology & Oncology · Summit, NJ
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Lahey Clinic, Inc. $176,508
- Dana-Farber Cancer Institute $113,082
- Morristown Medical Center, NJ $83,308
- Northside Hospital Gwinnett, GA $28,523
- Mount Sinai Medical Center of Florida, Inc, FL $6,750
- Tampa General Hospital, FL $770
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.